Similar articles

• Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

  International Breast Cancer Study Group (IBCSG). International Breast Cancer Study Group (IBCSG). J Natl Cancer Inst. 2002 Jul 17;94(14):1054-65. doi: 10.1093/jnci/94.14.1054. J Natl Cancer Inst. 2002. PMID: 12122096 Clinical Trial.
• Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

  Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Viale G, et al. J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393. J Clin Oncol. 2008. PMID: 18349391 Clinical Trial.
• Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

  Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG. Fisher B, et al. J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82. doi: 10.1093/jnci/89.22.1673. J Natl Cancer Inst. 1997. PMID: 9390536 Clinical Trial.
• [No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].

  Heidemann E. Heidemann E. Strahlenther Onkol. 1998 May;174(5):290-1. doi: 10.1007/BF03038727. Strahlenther Onkol. 1998. PMID: 9614963 Review. German. No abstract available.
• Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.

  Pritchard KI. Pritchard KI. Oncology (Williston Park). 2009 Jan;23(1):27-33. Oncology (Williston Park). 2009. PMID: 19283918 Review.